Total Visits

Views
Early tumour shrinkage (ETS) and depth of response (DpR) with first-line panitumumab (P) plus FOLFOX4 (P-FOLFOX4) or FOLFIRI (P-FOLFIRI) in patients (pts) with wild-type (WT) RAS colorectal cancer (CRC) and liver-limited disease (LLD)35

Select a period of time:

Views

Views
March 20200
April 20206
May 20208
June 20203
July 20200
August 202012
September 20205
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States19
Ireland13
Spain1
India1
 

Top cities views

Views
West Palm Beach19
Dublin13
Jaipur1
Valencia1